Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Surface Protein gp120 Overview | 8 | 1 |
| Therapeutics Development | 9 | 3 |
| Surface Protein gp120 Products under Development by Stage of Development | 9 | 1 |
| Surface Protein gp120 Products under Development by Therapy Area | 10 | 1 |
| Surface Protein gp120 Products under Development by Indication | 11 | 1 |
| Surface Protein gp120 Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Surface Protein gp120 Products under Development by Companies | 14 | 2 |
| Surface Protein gp120 Products under Development by Universities/Institutes | 16 | 2 |
| Surface Protein gp120 Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Surface Protein gp120 Companies Involved in Therapeutics Development | 24 | 6 |
| GlaxoSmithKline Plc | 24 | 1 |
| Osel, Inc. | 25 | 1 |
| Sanofi Pasteur SA | 26 | 1 |
| TeneoBio Inc | 27 | 1 |
| United Biomedical, Inc. | 28 | 1 |
| ViiV Healthcare Limited | 29 | 1 |
| Surface Protein gp120 Drug Profiles | 30 | 29 |
| Abzentek Drug Profile | 30 | 1 |
| AIDSVAX B/B + ALVAC-HIV vCP1521 Drug Profile | 31 | 2 |
| Biologic for Infectious Disease Drug Profile | 33 | 2 |
| BMD-101 Drug Profile | 35 | 1 |
| BMD-104 Drug Profile | 36 | 1 |
| BMS-585248 Drug Profile | 37 | 1 |
| DS-003 Drug Profile | 38 | 1 |
| fostemsavir tromethamine Drug Profile | 39 | 3 |
| HIV [strains C1086 + TV1] (bivalent) vaccine Drug Profile | 42 | 1 |
| HIV vaccine Drug Profile | 43 | 1 |
| HIV vaccine Drug Profile | 44 | 1 |
| HIV vaccine 1 Drug Profile | 45 | 1 |
| HIV-1 vaccine Drug Profile | 46 | 1 |
| HNG-156 Drug Profile | 47 | 1 |
| M-48U1 Drug Profile | 48 | 1 |
| Monoclonal Antibodies to Inhibit GP120 for HIV Drug Profile | 49 | 1 |
| Monoclonal Antibodies to Inhibit Gp120 for HIV-1 Infection Drug Profile | 50 | 1 |
| Monoclonal Antibodies to Target GP120 and GP41 for HIV Drug Profile | 51 | 1 |
| Monoclonal Antibody to Inhibit Glycoprotein 120 for HIV Drug Profile | 52 | 1 |
| Recombinant Peptide to Inhibit gp120 for HIV-1 Drug Profile | 53 | 1 |
| Recombinant Protein to Target gp120 for HIV-1 Infections Drug Profile | 54 | 1 |
| Small Molecules to Target GP120 and Gp41 for HIV-1 Infections Drug Profile | 55 | 1 |
| Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection Drug Profile | 56 | 1 |
| VCP-2438 Drug Profile | 57 | 1 |
| VRC-01LS Drug Profile | 58 | 1 |
| Surface Protein gp120 Dormant Projects | 59 | 3 |
| Surface Protein gp120 Discontinued Products | 62 | 1 |
| Surface Protein gp120 Featured News &Press Releases | 63 | 11 |
| May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa | 63 | 1 |
| Jan 07, 2016: National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology | 64 | 1 |
| Dec 02, 2015: Abzyme Research Foundation's Inaugural ENDHIV BALL Launches $3 Million Fund for New Therapeutic HIV Vaccine Trial | 64 | 1 |
| Jul 21, 2015: Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients | 65 | 1 |
| Jul 08, 2015: Scripps research-designed drug candidate significantly reduces HIV reactivation rate | 66 | 1 |
| Feb 25, 2015: 48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation | 67 | 1 |
| Oct 03, 2014: Bristol-Myers Squibb Presents Data of BMS-663068 at IDWeek 2014 Showcasing Continued Innovation in Virology | 68 | 1 |
| Jul 30, 2014: Dissolvable fabric loaded with medicine might offer faster protection against HIV | 69 | 1 |
| Mar 05, 2014: Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients | 70 | 1 |
| May 06, 2013: Duke Researchers Report Additional Information From Phase III HIV Vaccine Trial In Thailand | 71 | 1 |
| Dec 06, 2012: Vaginal microbicide gel may offer a promising strategy for prevention and protection against HIV transmission | 72 | 2 |
| Appendix | 74 | 2 |
| Methodology | 74 | 1 |
| Coverage | 74 | 1 |
| Secondary Research | 74 | 1 |
| Primary Research | 74 | 1 |
| Expert Panel Validation | 74 | 1 |
| Contact Us | 74 | 1 |
| Disclaimer | 75 | 1 |